{
    "id": 29536,
    "fullName": "KANK2 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KANK2-ALK results from the fusion of KANK2 and ALK, leading to cell transformation in culture and tumorigenesis in animal models (PMID: 30518629). KANK2-ALK has been identified in leiomyosarcoma (PMID: 30518629).",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25959,
        "geneSymbol": "KANK2",
        "terms": [
            "KANK2",
            "ANKRD25",
            "MXRA3",
            "NPHS16",
            "PPKWH",
            "SIP"
        ]
    },
    "variant": "KANK2 - ALK",
    "createDate": "03/07/2019",
    "updateDate": "03/07/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 16297,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk phosphorylation, cell growth, and colony formation in transformed cell lines expressing KANK2-ALK in culture (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16302,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited cell growth and colony formation in transformed cell lines expressing KANK2-ALK in culture (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16298,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) inhibited Alk phosphorylation, cell growth, and colony formation in transformed cell lines expressing KANK2-ALK in culture (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16306,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk and Erk phosphorylation in smooth muscle cells expressing KANK2-ALK in culture, resulted in modest improvement of survival in cell line xenograft models (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4230,
                "name": "smooth muscle cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16299,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited Alk phosphorylation, cell growth, and colony formation in transformed cell lines expressing KANK2-ALK in culture (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited cell growth and colony formation in transformed cell lines expressing KANK2-ALK in culture (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16305,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk and Erk phosphorylation in smooth muscle cells expressing KANK2-ALK in culture, resulted in tumor regression and prolonged survival in cell line xenograft models (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4230,
                "name": "smooth muscle cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31582,
            "profileName": "KANK2 - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 19300,
                    "name": "ALK Inhibitor",
                    "profileName": "KANK2 - ALK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}